Fact-checked by Grok 2 weeks ago

Mycobacterium tuberculosis complex

The Mycobacterium tuberculosis complex (MTBC) is a group of closely related species of mycobacteria that serve as the primary causative agents of tuberculosis (TB), a contagious infectious disease affecting humans and a range of animals.^[1] These pathogens are characterized as aerobic, non-spore-forming, non-motile, rod-shaped bacilli with a distinctive high-lipid cell wall rich in mycolic acids, which confers acid-fast staining properties and enables intracellular survival within host macrophages.^[1] The complex exhibits slow growth, with a generation time of approximately 20 hours, often requiring 3 to 8 weeks for visible colonies on solid media.^[1] Key member species include Mycobacterium tuberculosis (the predominant human pathogen), M. bovis (associated with zoonotic transmission from cattle), M. africanum (prevalent in West Africa), M. microti (affecting rodents and occasionally humans), M. caprae (linked to goats), M. pinnipedii (found in seals and sea lions), and M. canettii (a rare human isolate considered evolutionarily basal).^[2] Members of the MTBC are genetically monomorphic, sharing over 99.9% sequence identity due to recent evolutionary divergence from a common ancestor, with differences arising primarily from deletions and insertions in regions of difference (RD1–RD14).^[2] Transmission occurs primarily through airborne droplet nuclei (1–5 microns in size) generated by coughing, sneezing, speaking, or singing by individuals with active pulmonary or laryngeal TB, typically requiring prolonged close contact in poorly ventilated indoor settings for infection to establish.^[3] Upon inhalation, bacilli are phagocytosed by alveolar macrophages but evade killing through mechanisms like phagosome arrest and immune modulation, leading to either latent infection (asymptomatic, non-infectious granulomas) in about 90% of cases or active disease in 5–10% (often within the first two years or later due to immunosuppression).^[1] Active TB manifests as pulmonary disease (e.g., persistent cough >3 weeks, hemoptysis, chest pain, weight loss, night sweats, and fever) in ~85% of cases, or extrapulmonary involvement (e.g., lymph nodes, pleura, spine, kidneys, or meninges) in the remainder, with symptoms varying by site.^[3] Globally, the MTBC imposes a profound public health burden, infecting an estimated one-quarter of the world's population latently while driving active disease as the leading cause of death from a single infectious agent (other than SARS-CoV-2).^[4] In 2024, there were 10.7 million new TB cases (incidence of 132 per 100,000 population), resulting in 1.23 million deaths (1.08 million among HIV-negative individuals and 150,000 among HIV-positive), with the highest burdens in the South-East Asia Region (34% of cases), African Region (25%), and the Western Pacific Region (27%).^[5] Drug-resistant forms, such as multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB), affected ~400,000 cases, complicating treatment and control efforts, while HIV co-infection occurred in about 5.3% of new cases (570,000 people).^[5] Despite being preventable and curable with regimens like rifampin-based therapy, TB's persistence underscores the need for enhanced diagnostics, vaccines beyond BCG, and global funding to meet Sustainable Development Goal targets for incidence reduction by 2030.^[5]

Taxonomy and Phylogenetics

Definition and Member Species

The Mycobacterium tuberculosis complex (MTBC) is defined as a monophyletic clade within the genus Mycobacterium, comprising closely related bacterial species that are primarily pathogenic to humans and animals, capable of causing tuberculosis-like diseases.^[6] This taxonomic grouping was first proposed in 2002 by Brosch et al., based on comparative genomic analyses revealing tight clustering among these species.^[6] The MTBC represents a genetically homogeneous group, distinguished from other mycobacteria by their shared evolutionary bottleneck and adaptation to specific hosts.^[7] Members of the MTBC exhibit approximately 99.9% nucleotide sequence identity across their genomes, enabling them to cause similar disease manifestations despite variations in host tropism and minor phenotypic differences.^[6]^[7] These species demonstrate distinct host preferences, with most being adapted to either humans or particular animal reservoirs, though zoonotic transmission occurs in some cases; for instance, M. bovis primarily causes bovine tuberculosis in cattle but can infect humans through consumption of unpasteurized milk and dairy products.^[8] The primary member species include:

Mycobacterium tuberculosis: Human-adapted, the main causative agent of human tuberculosis.^[7]
M. bovis: Cattle-adapted, with zoonotic potential to humans and other mammals.^[7]
M. africanum: Associated with human infections, particularly in West African populations.^[7]
M. microti: Rodent-adapted, occasionally infecting other small mammals and humans.^[7]
M. caprae: Goat-adapted, also affecting sheep, cattle, and wildlife like wild boar.^[7]
M. pinnipedii: Seal- and sea lion-adapted, with reports in other marine mammals.^[7]
M. mungi: Banded mongoose-adapted, causing tuberculosis in mongoose populations in Africa.^[7]
M. orygis: Primarily animal-adapted (e.g., oryx), but associated with human tuberculosis cases in South Asia.^[7]
M. canettii: Rare human pathogen, considered evolutionarily basal to the complex.^[9]

Evolutionary History and Relationships

Recent genomic studies estimate the Mycobacterium tuberculosis complex (MTBC) emerged approximately 2,000–5,000 years ago, likely in Africa, from a progenitor resembling Mycobacterium canettii, though older estimates of 40,000–70,000 years exist based on earlier data.^[10]^[11]^[12] This origin aligns with genetic analyses indicating that the common ancestor was likely a human-adapted pathogen, rather than acquired from animals, marking the beginning of a co-evolutionary relationship with Homo sapiens.^[13] The complex's diversification reflects human demographic expansions, with early clades spreading alongside migratory patterns from the Horn of Africa. Under recent models, key divergence events within the MTBC include splits into human-adapted and animal-adapted lineages occurring within the last few thousand years, with animal-adapted species such as M. bovis associated with cattle domestication around 10,000 years ago but likely specializing later in the Near East or Africa.^[10]^[14] Human-adapted strains diversified into six principal lineages (Lineages 1–6), each showing geographic associations: Lineage 1 (Indo-Oceanic) prevalent in Asia and East Africa, Lineage 2 (East Asian/Beijing) in East Asia, Lineage 3 (East African-Indian) in East Africa and India, Lineage 4 (Euro-American) globally distributed, Lineage 5 (M. africanum West African) in West Africa, and Lineage 6 (M. africanum West African 2) also in West Africa.^[15] These divergences are characterized by limited genetic exchange, underscoring the MTBC's adaptation to specific host populations. The phylogenetic structure of the MTBC exhibits a clonal population architecture with remarkably low genetic diversity, attributable to a recent evolutionary bottleneck that reduced variability following its emergence.^[16] This bottleneck is evidenced by whole-genome sequencing revealing fewer single-nucleotide polymorphisms (SNPs) compared to other bacterial pathogens of similar age, with diversification occurring primarily through drift and selection within lineages rather than recombination.^[17] Classification relies on methods like spoligotyping, which targets CRISPR spacer deletions, and variable number tandem repeats (VNTR) analysis, enabling lineage assignment and outbreak tracking with high resolution when combined.^[18] Ancient DNA studies provide direct evidence of the MTBC's antiquity, including MTBC DNA detected in a 17,000-year-old bison metacarpal from Wyoming, USA, via PCR amplification of insertion sequences and spoligotyping, indicating early presence in Pleistocene North America and possible cross-species transmission—though this predates some recent MRCA estimates and remains debated.^[19] Similarly, MTBC sequences, including IS6110 and the mtp40 fragment, have been amplified from medieval European human skeletons (circa 10th–14th centuries) showing osteological tuberculosis lesions, confirming M. tuberculosis (not M. bovis) infection and genetic continuity with modern strains.^[20] The MTBC represents a specialized subset of slow-growing mycobacteria, having undergone extensive gene loss relative to environmental or non-pathogenic relatives like M. canettii or saprophytic species, particularly in pathways for nutrient scavenging, stress response, and free-living persistence in soil or water.^[21] This reductive evolution, involving pseudogenization of over 100 genes, facilitated obligate parasitism in mammalian hosts by eliminating traits unnecessary for intracellular survival, while enhancing virulence factors like ESX secretion systems.^[22]

Biological Characteristics

Morphology and Physiology

Members of the Mycobacterium tuberculosis complex (MTBC) are rod-shaped bacilli, typically measuring 0.2–0.6 μm in width and 2–4 μm in length, appearing as straight or slightly curved rods under microscopy.^[23] These bacteria are non-motile and non-spore-forming, lacking flagella or other structures for locomotion and reproduction via endospores.^[24] A defining feature is their acid-fast staining property, which results from the high concentration of mycolic acids in the cell wall; these long-chain fatty acids bind the dye carbol fuchsin, rendering the cells resistant to decolorization by acid-alcohol, thus appearing red against a blue background in Ziehl-Neelsen or Kinyoun stains.^[25] The cell wall of MTBC species is exceptionally complex and lipid-rich, comprising an inner layer of peptidoglycan covalently linked to arabinogalactan, which in turn is esterified to mycolic acids forming the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex.^[26] This structure, often described as a waxy outer membrane or mycomembrane, accounts for up to 60% of the cell wall's dry weight in lipids, providing a formidable permeability barrier.^[27] The high lipid content confers intrinsic resistance to desiccation by preventing water loss, to many antibiotics by limiting drug penetration, and to host immune defenses such as lysosomal enzymes and reactive oxygen species through impermeability and low fluidity.^[28] MTBC bacteria are obligate aerobes, requiring molecular oxygen for respiration and growth, with optimal conditions at 37°C, the human body temperature.^[29] They exhibit slow growth, with a generation time or doubling time of approximately 15–20 hours in vitro, far longer than most bacteria, leading to visible colonies only after 2–8 weeks of incubation.^[30] On Lowenstein-Jensen (LJ) medium, an egg-based solid agar, MTBC forms characteristic rough, dry, buff- or cream-colored colonies that are non-pigmented and adhere firmly to the medium, reflecting their eugonic growth pattern.^[31] Metabolically, MTBC species are asaccharolytic, unable to ferment carbohydrates and instead relying on oxidative metabolism of lipids, amino acids, and other non-sugar carbon sources for energy.^[32] A key diagnostic trait for distinguishing human-adapted MTBC members like M. tuberculosis (and some M. africanum strains) from other mycobacteria and animal-adapted MTBC members is the accumulation and synthesis of niacin (nicotinic acid), which is detected via a colorimetric test on cultures grown on niacin-containing media like LJ; positive results confirm M. tuberculosis or related strains and distinguish it from most other mycobacteria.^[33] They are also catalase-positive, producing the enzyme that decomposes hydrogen peroxide into water and oxygen, but the catalase is heat-labile, losing activity after 20 minutes at 68°C, aiding in species differentiation from catalase-stable nontuberculous mycobacteria.^[34] MTBC demonstrates notable environmental resilience, surviving in aerosolized droplet nuclei for several hours due to the protective cell wall that resists drying and UV exposure in air.^[35] This durability facilitates airborne transmission. Additionally, the bacteria exhibit resistance to chlorine-based disinfectants, requiring concentrations of 1,000 ppm or higher for effective inactivation, compared to much lower levels for common pathogens like E. coli, which contributes to their persistence in treated water systems.^[36]

Genomic Organization

The genome of the Mycobacterium tuberculosis complex (MTBC) consists of a single circular chromosome approximately 4.4 million base pairs (Mb) in length, encoding around 4,000 genes, with a guanine-cytosine (GC) content of 65.6%.^[37] This structure reflects a compact organization typical of obligate pathogens, with minimal presence of plasmids and limited evidence of horizontal gene transfer, contributing to the complex's genetic stability across its members.^[38] Key genomic regions distinguish the MTBC from other mycobacteria, including the region of difference 1 (RD1), which is unique to the complex and spans about 9.4 kilobases, encoding components of the ESX-1 type VII secretion system essential for protein export.^[39] Repetitive elements, such as the insertion sequence IS6110, are prevalent, with copy numbers varying from 0 to over 20 per strain, enabling restriction fragment length polymorphism (RFLP) analysis for molecular strain typing and epidemiological tracking.^[40] The gene content of MTBC genomes features approximately 80 pseudogenes (average across strains), indicative of reductive evolution that has streamlined metabolic and regulatory pathways for host adaptation.^[41] Essential gene clusters include the dosR regulon, comprising at least 48 genes that respond to hypoxic conditions by modulating dormancy and persistence mechanisms.^[42] Strain variation within the MTBC arises from lineage-specific deletions, such as the RD9 region absent in certain lineages like Lineage 2 (East Asian/Beijing), which influences phylogenetic classification.^[43] Whole-genome sequencing (WGS) has become a primary tool for detecting these mutations, including single nucleotide polymorphisms (SNPs) and insertions/deletions, facilitating high-resolution analysis of diversity and evolution.^[44] Comparative genomics reveals over 99.95% nucleotide identity across MTBC species, underscoring their clonal nature, though animal-adapted strains like M. bovis exhibit fixed mutations in the pncA gene conferring natural resistance to pyrazinamide.^[38]^[45]

Pathogenesis and Immunology

Infection Mechanisms

The Mycobacterium tuberculosis complex (MTBC) primarily infects humans through the respiratory route, with transmission occurring via inhalation of aerosolized droplets containing as few as 1–3 bacilli expelled from the respiratory tract of infected individuals.^[46] These droplets, typically 1–5 μm in diameter, evade mucociliary clearance and deposit in the alveoli, where the bacilli are rapidly phagocytosed by resident alveolar macrophages, serving as the initial cellular target for infection establishment.^[47] Upon uptake, MTBC bacilli are internalized by alveolar macrophages primarily through complement receptors, such as CR1 (CD35) and CR3 (CD11b/CD18), which facilitate non-opsonic phagocytosis without triggering robust inflammatory responses.^[48] Intracellular survival is achieved by arresting phagosome maturation, notably through inhibition of phagosome-lysosome fusion mediated by the ESX-1 type VII secretion system, which secretes effectors like ESAT-6 and CFP-10 to disrupt vacuolar trafficking and promote phagosomal permeabilization.^[49] Additionally, lipoarabinomannan (LAM), a glycolipid component of the mycobacterial cell wall, contributes to this evasion by binding to mannose receptors on macrophages and interfering with endosomal acidification and fusion processes.^[50] Key virulence factors enhance MTBC's ability to invade and persist within host cells. The cord factor, trehalose 6,6'-dimycolate (TDM), promotes the characteristic serpentine cord formation observed in vitro, facilitating bacterial aggregation and resistance to phagocytosis while inducing granulomatous inflammation.^[51] Secreted proteins of the antigen 85 (Ag85) complex, including Ag85A, Ag85B, and Ag85C, function as mycolyltransferases essential for synthesizing trehalose monomycolate and cell wall arabinogalactan, thereby maintaining structural integrity during intracellular replication.^[52] Following intracellular replication, MTBC induces granuloma formation as a hallmark of infection. Infected macrophages release chemokines that recruit additional immune cells, including monocytes and lymphocytes, leading to the aggregation of epithelioid macrophages around clusters of bacilli and culminating in caseous necrosis—a cheese-like central core of dead cells and tissue debris that limits but does not eradicate the infection.^[53] Bacilli can disseminate from the primary site via lymphatic channels to regional lymph nodes, establishing secondary foci that contribute to both containment and potential reactivation.^[54] In most cases (approximately 90%), primary infection is initially controlled by the host, resulting in subclinical infection where bacilli persist in low-oxygen niches such as hypoxic granuloma centers or intracellular compartments, entering a dormant state that evades sterilizing immunity.^[47]^[55] In contrast, progressive infection occurs in a minority of cases, characterized by unchecked bacterial proliferation, extensive tissue destruction, and dissemination beyond the lungs.^[47]

Host Immune Response and Latency

Upon inhalation, Mycobacterium tuberculosis complex (MTBC) bacilli are phagocytosed by alveolar macrophages, triggering innate immune responses primarily through pattern recognition receptors such as Toll-like receptor 2 (TLR2), which recognizes lipoproteins, while lipoarabinomannan binds to the mannose receptor.^[56]^[57] These interactions lead to macrophage activation and the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12).^[58] TNF-α promotes granuloma formation and restricts bacterial growth, while IL-12 drives the differentiation of T helper 1 (Th1) cells, bridging innate and adaptive immunity.^[59] Additional innate effectors, such as dendritic cells and natural killer cells, contribute by enhancing antigen presentation and releasing interferon-gamma (IFN-γ), which activates macrophages to form phagolysosomes for bacterial containment.^[56] The adaptive immune response is critical for controlling MTBC infection, with CD4+ T cells playing a central role in orchestrating a Th1-biased response characterized by IFN-γ secretion.^[58] IFN-γ induces macrophage expression of nitric oxide synthase and other antimicrobial effectors, enhancing intracellular killing of the pathogen.^[59] CD8+ T cells provide cytotoxic activity by recognizing MTBC antigens presented on MHC class I molecules, lysing infected cells and releasing granzymes to limit bacterial dissemination.^[60] B cells contribute through antibody production, though their role is secondary to cellular immunity in containing infection.^[58] Collectively, these responses culminate in the formation of granulomas—organized structures comprising macrophages, T cells, and fibroblasts—that encapsulate bacilli, preventing systemic spread in most immunocompetent hosts.^[59] MTBC establishes latency by entering a non-replicating persistent state within hypoxic, nutrient-limited granuloma environments, allowing long-term survival without active replication.^[61] This dormancy is regulated by the DosR regulon, a network of approximately 50 genes activated under low-oxygen conditions to reprogram metabolism, including upregulation of nitrate reduction and triacylglycerol synthesis for energy storage.^[62] The DosR transcription factor, responsive to gaseous nitric oxide and carbon monoxide, enables bacterial adaptation to stress, promoting tolerance to antibiotics and immune pressures.^[62] Reactivation from latency can be triggered by immunosuppression, such as HIV co-infection, which impairs CD4+ T cell function and disrupts granuloma integrity, leading to bacterial proliferation.^[55] To evade host immunity, MTBC employs strategies that subvert both innate and adaptive responses, including downregulation of MHC class I expression on infected macrophages to reduce CD8+ T cell recognition.^[63] The pathogen also inhibits apoptosis in host cells by secreting proteins like LpqH and SecA2 that block caspase activation and promote anti-apoptotic pathways, allowing intracellular persistence and spread to neighboring cells via necrosis.^[64] These mechanisms preserve the bacterial niche while minimizing inflammatory clearance, contributing to chronic infection.^[65] Host genetic factors significantly influence MTBC susceptibility and progression to active disease, with polymorphisms in the SLC11A1 (formerly NRAMP1) gene being a well-established example.^[66] SLC11A1 encodes a proton-divalent cation transporter on phagosomal membranes that restricts bacterial growth by limiting iron availability; variants like the 3' untranslated region alleles are associated with increased tuberculosis risk across diverse populations.^[67] These polymorphisms impair macrophage antimicrobial activity, highlighting the interplay between host genetics and immune response efficacy in determining infection outcomes.^[68]

Clinical Aspects

Disease Manifestations

Primary tuberculosis (TB) infection, typically occurring in individuals without prior exposure to the Mycobacterium tuberculosis complex (MTBC), is often asymptomatic or presents with mild, flu-like symptoms such as low-grade fever, malaise, and occasional cough.^[69] In many cases, the infection leads to the formation of a Ghon complex, characterized by a small granulomatous lesion (Ghon focus) in the middle or lower lung zones accompanied by regional lymph node involvement, which may calcify over time as a Ranke complex.^[70] This primary response confines the infection, establishing latency in approximately 90-95% of cases.^[71] Pulmonary TB accounts for about 85% of active TB cases and manifests with progressive symptoms including persistent cough, often productive and sometimes accompanied by hemoptysis, along with fever, night sweats, weight loss, and fatigue.^[72]^[1] The disease preferentially affects the upper lung lobes, where higher oxygen tension favors bacterial proliferation, leading to tissue necrosis and cavitation that exacerbates cough and transmission risk.^[73] Granuloma formation plays a key role in containing the infection but can contribute to local tissue damage in active disease.^[70] Progression from latent to active TB occurs in 5-10% of infected individuals over their lifetime, with higher risk in the first two years post-infection or under conditions of immunosuppression.^[71] In immunocompromised hosts, such as those with HIV, disseminated miliary TB may develop, featuring widespread millet-seed-like lesions across the lungs due to hematogenous spread.^[74] Diagnostic indicators of MTBC exposure include a positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA), which detect immune sensitization but do not distinguish latent from active disease without clinical correlation.^[71] Untreated or severe pulmonary TB can result in extensive lung damage, including fibrosis and bronchiectasis, which impair airflow and gas exchange, potentially progressing to chronic respiratory failure.^[75]^[76] These structural changes reduce overall lung function and increase susceptibility to secondary infections, underscoring the need for early intervention.^[77]

Extrapulmonary Tuberculosis

Extrapulmonary tuberculosis (EPTB) refers to tuberculosis infection involving sites outside the lungs, accounting for approximately 15-20% of all TB cases globally, with lymph nodes being the most frequent site at around 40% of EPTB instances.^[78] Common affected areas also include the pleura, bones and joints, meninges, and genitourinary system.^[72] In the lymphatic system, particularly cervical lymph nodes, infection often presents as scrofula, characterized by painless lymphadenopathy that may progress to form cold abscesses without significant inflammation or fever.^[79] Pleural involvement typically manifests as tuberculous pleural effusion, a unilateral accumulation of fluid in the pleural space, often presenting with chest pain and dyspnea following primary pulmonary infection.^[80] Skeletal tuberculosis, known as Pott's disease when affecting the spine, commonly involves the vertebral bodies and can lead to chronic back pain, kyphotic deformities, and neurological deficits due to spinal cord compression.^[80] Central nervous system tuberculosis, primarily tuberculous meningitis, often develops as a basal exudative process that encases the brainstem and cranial nerves, resulting in headaches, altered mental status, and palsies of cranial nerves III, VI, and VII. Genitourinary tuberculosis frequently presents with sterile pyuria, where urine shows white blood cells but no bacterial growth on standard culture, alongside symptoms such as dysuria, hematuria, and renal colic from involvement of the kidneys, ureters, or bladder.^[81] Zoonotic forms caused by Mycobacterium bovis, often acquired through ingestion of unpasteurized milk or undercooked meat, predominantly affect extrapulmonary sites like the abdomen, leading to peritoneal or intestinal tuberculosis with symptoms including ascites and abdominal pain.^[82] EPTB occurs at higher rates in children and individuals with HIV infection, where dissemination is more likely due to immature or impaired immune responses, respectively.^[83] Disseminated EPTB, including miliary tuberculosis, arises in about 15% of cases, particularly with delayed diagnosis, immunosuppression, or young age, and serves as a risk factor for multi-organ involvement.^[84] While EPTB generally progresses more slowly than pulmonary forms, central nervous system involvement carries a higher mortality rate of 10-20%, often due to hydrocephalus, infarction, or delayed treatment.^[85]

Epidemiology

Global Burden and Distribution

The Mycobacterium tuberculosis complex (MTBC) causes tuberculosis (TB), which remains one of the leading infectious disease killers worldwide. According to the World Health Organization (WHO) Global Tuberculosis Report 2025, an estimated 10.7 million people developed TB in 2024, corresponding to an incidence rate of 131 cases per 100,000 population (95% UI: 122–141).^[5] This represents a nearly 2% decline from 2023, while total TB deaths reached 1.23 million (95% UI: 1.13–1.33 million), including 1.08 million among HIV-negative individuals (95% UI: 0.99–1.18 million) and 150,000 among those with HIV (95% UI: 120,000–183,000).^[5] These figures underscore the persistent global burden, particularly in low- and middle-income countries (LMICs), where the majority of cases occur. Geographically, the TB burden is highly concentrated, with the WHO South-East Asia Region accounting for approximately 46% of global cases, the African Region for 25%, and the Western Pacific Region for 18%. Among individual countries, India bears the largest share at 25% of global cases, followed by Indonesia (10%), the Philippines (6.8%), China (6.5%), Pakistan (6.3%), Nigeria (4.8%), the Democratic Republic of the Congo (3.9%), and Bangladesh (3.6%).^[5] In contrast, high-income regions like Western Europe exhibit low incidence rates, typically below 10 cases per 100,000 population, with the European WHO Region overall contributing only about 2% of global cases. These disparities highlight endemic patterns in populous, resource-limited settings versus near-elimination in affluent areas with robust health systems.^[86] TB often intersects with other epidemics, notably HIV, with approximately 5.8% of 2024 cases (~621,000 people) occurring among those living with HIV, predominantly in the African Region. Incidence is also rising among vulnerable populations, including migrants in low-burden countries—where foreign-born individuals account for over 70% of cases in places like the United States and Western Europe—and in correctional facilities, where rates can be 10–100 times higher than in the general population due to overcrowding and limited healthcare access. These co-epidemics and hotspots exacerbate the overall burden, straining public health resources in affected communities.^[5]^[87]^[86] Historically, TB incidence declined sharply in high-income countries after the 1950s, driven by the introduction of effective antibiotics like streptomycin and isoniazid, alongside improved living standards and public health measures. Globally, however, progress has stagnated since 2015, with only about a 10% reduction in incidence rates by 2024—well short of the WHO End TB Strategy's 50% target for 2025. The COVID-19 pandemic disrupted diagnostics, treatment, and surveillance, leading to an estimated 100,000 excess TB deaths in 2020–2021 and a rebound in cases, reversing prior gains in many regions. From 2023 to 2024, incidence declined by nearly 2% and deaths by 3%, marking initial recovery.^[5] The economic toll of MTBC-driven TB is profound, accounting for approximately 25 million disability-adjusted life years (DALYs) lost annually through premature mortality and morbidity. In low-income countries, the direct and indirect costs—including healthcare expenditures, lost productivity, and social protection needs—total around $13 billion yearly, representing a significant drain on fragile economies and perpetuating poverty cycles among affected households.^[88]

Transmission Dynamics and Risk Factors

The Mycobacterium tuberculosis complex (MTBC) primarily spreads through airborne transmission, where infectious droplet nuclei containing viable bacilli are generated by activities such as coughing, sneezing, speaking, or singing by individuals with active pulmonary tuberculosis.^[89] These droplet nuclei, typically 1–5 μm in diameter, can remain suspended in the air for hours and are inhaled by susceptible individuals in close proximity.^[90] The minimal infectious dose is low, estimated at 1–10 bacilli, allowing infection to occur even with brief exposure under favorable conditions.^[91] Transmission requires prolonged or repeated close contact, such as in household settings, where the secondary attack rate for infection among contacts can reach approximately 30–50%, depending on factors like exposure duration and index case infectiousness.^[92] Casual contact, fomites, or indirect surfaces do not facilitate spread, as MTBC does not survive well outside the respiratory tract or on environmental surfaces.^[93] Infectiousness varies significantly among cases, with smear-positive pulmonary tuberculosis patients being the most contagious due to higher bacillary loads in sputum, capable of generating thousands of infectious particles per minute.^[94] In contrast, smear-negative cases contribute minimally to transmission, estimated at 13–20% of overall spread.^[95] Environmental controls like ultraviolet (UV) light irradiation and improved ventilation can substantially reduce airborne viability; upper-room UV systems have demonstrated up to 80% reduction in transmission risk in shared spaces, while increasing air exchange rates to 6–12 per hour dilutes infectious particles effectively.^[96] In high-burden settings, the basic reproduction number (_R_0), representing the average number of secondary infections from one case in a susceptible population, is estimated at 2.5–3, reflecting moderate contagiousness influenced by contact patterns and immunity levels.^[97] Key risk factors for developing active tuberculosis following exposure include immunosuppression and socioeconomic conditions. HIV co-infection increases the risk of progression from latent to active disease by up to 20-fold, due to impaired cellular immunity essential for containing MTBC.^[98] Diabetes mellitus elevates risk approximately 3-fold by altering macrophage function and promoting hyperglycemia-favorable bacterial growth.^[99] Smoking doubles the risk through lung epithelial damage and reduced immune clearance, while malnutrition and overcrowding further amplify susceptibility by weakening host defenses and increasing exposure opportunities, respectively.^[99] In active cases, roughly 50% arise from recent transmission rather than reactivation of latent infection, particularly in endemic areas with high community circulation.^[100] Zoonotic transmission within the MTBC occurs mainly through M. bovis, acquired via consumption of raw milk or unpasteurized dairy products from infected cattle, accounting for up to 10% of human tuberculosis cases in regions with limited pasteurization and high bovine prevalence, such as parts of Africa and Latin America.^[101] This route underscores the importance of distinguishing MTBC species in surveillance, as M. bovis often presents with extrapulmonary involvement and pyrazinamide resistance.^[102]

Diagnosis

Microbiological Methods

Microbiological diagnosis of the Mycobacterium tuberculosis complex (MTBC) begins with appropriate sample collection to ensure viable organisms for subsequent testing. For pulmonary tuberculosis, expectorated or induced sputum is the primary specimen, while extrapulmonary sites require biopsies from tissues such as lymph nodes or pleura, and cerebrospinal fluid (CSF) for suspected tuberculous meningitis.^[103] Specimens from non-respiratory sources, like CSF or tissue, are typically processed directly without decontamination due to lower bacterial load, whereas respiratory samples undergo decontamination to eliminate contaminating flora.^[104] Decontamination of sputum and other respiratory specimens uses N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH), a mucolytic and alkaline method that liquefies mucus and kills non-mycobacterial organisms while preserving MTBC viability. The standard protocol involves mixing the specimen with 2% NaOH and 0.5% NALC, neutralizing with phosphate buffer, and concentrating by centrifugation before further analysis.^[105] Direct detection via smear microscopy employs Ziehl-Neelsen (ZN) staining to identify acid-fast bacilli (AFB), where MTBC retain carbol fuchsin dye due to their mycolic acid-rich cell walls, appearing red against a blue background under light microscopy. This rapid method, providing results within hours, has a sensitivity of 50–80% in high-burden settings with high bacterial loads, such as cavitary disease, but lower (around 30–50%) in paucibacillary cases.^[106] Fluorescence microscopy with auramine staining enhances sensitivity by 10–20% over ZN but requires specialized equipment.^[107] Culture remains the gold standard for MTBC isolation and confirmation, allowing viability assessment and drug susceptibility testing. Solid egg-based Löwenstein-Jensen (LJ) medium supports slow growth of MTBC colonies over 2–6 weeks at 37°C in 5–10% CO₂, while automated liquid systems like the Mycobacteria Growth Indicator Tube (MGIT) 960 detect growth via oxygen-quenched fluorescence in 1–3 weeks on average, improving yield by 10–20% and reducing turnaround time.^[108] Positive cultures are confirmed as MTBC using the p-nitrobenzoic acid (PNB) inhibition test, where MTBC growth is inhibited at 500 μg/ml PNB, distinguishing it from most nontuberculous mycobacteria (NTM) that are resistant.^[103] Within confirmed MTBC isolates, the niacin test can identify M. tuberculosis specifically, as it accumulates niacin (nicotinic acid), producing a yellow color with reagents like cyanogen bromide and ammonium sulfate; this test is negative for other MTBC members like M. bovis.^[109] Additional biochemical tests aid species identification within MTBC: for example, nitrate reduction is positive for M. tuberculosis (converting nitrate to nitrite, detectable by sulfanilamide-N-(1-naphthyl)ethylenediamine reagent) but negative for M. bovis; urease activity is generally negative or weak across MTBC but not reliably diagnostic. These traits, combined with slow growth and non-pigmentation, help differentiate MTBC members from rapid growers or pigmented NTM species. Molecular methods are now preferred for precise species identification due to biochemical variability.^[110] Handling MTBC requires biosafety level 3 (BSL-3) containment due to the high risk of aerosol transmission during manipulation, such as vortexing or subculturing, which can generate infectious droplet nuclei capable of causing laboratory-acquired tuberculosis. BSL-3 facilities include directional airflow, HEPA-filtered exhaust, and double-door access, with personnel using powered air-purifying respirators or N95 masks for procedures.^[111]

Molecular and Imaging Techniques

Molecular techniques play a crucial role in the rapid diagnosis of Mycobacterium tuberculosis complex (MTBC) infections, enabling the detection of bacterial DNA and associated drug resistance mutations directly from clinical specimens. Nucleic acid amplification tests (NAATs), such as the GeneXpert MTB/RIF assay (and its update, Xpert MTB/RIF Ultra, endorsed by WHO as of 2025), provide automated, cartridge-based detection of MTBC DNA and rifampin resistance within approximately 2 hours. This method exhibits high sensitivity ranging from 85% to 98% for pulmonary tuberculosis, particularly in smear-positive cases, and specificity exceeding 95%, making it a cornerstone for initial testing in high-burden settings.^[112]^[113]^[114] Line probe assays (LPAs) offer another molecular approach for detecting multidrug-resistant tuberculosis (MDR-TB) through reverse hybridization of amplified DNA with probes targeting key resistance genes, such as those for rifampin and isoniazid. These assays, including the GenoType MTBDRplus, deliver results in 1-2 days and are endorsed for use on smear-positive or culture-positive specimens, achieving sensitivities of 90-95% and specificities near 98% for first-line drug resistance detection. Whole-genome sequencing (WGS) extends this capability by comprehensively analyzing the MTBC genome to identify specific strains and resistance-conferring mutations, such as those in the rpoB gene for rifampin resistance, with predictive accuracies often surpassing 95% when aligned against phenotypic data. WGS is increasingly integrated into clinical workflows for outbreak investigations and personalized treatment planning, supported by catalogues of validated mutations.^[115]^[116] Imaging modalities complement molecular diagnostics by visualizing pathological changes in MTBC infections. Chest X-rays are the primary radiographic tool, revealing characteristic findings such as upper lobe infiltrates, cavities, or consolidation in active pulmonary tuberculosis, with a sensitivity of about 70-90% for symptomatic cases when interpreted alongside clinical symptoms. Computed tomography (CT) scans enhance detection of subtle or extrapulmonary features, including miliary patterns indicative of disseminated disease, offering higher resolution for early lesions and lymph node involvement. Positron emission tomography-computed tomography (PET-CT) using 18F-fluorodeoxyglucose (FDG) is particularly valuable for assessing latent TB activity, as it highlights metabolically active granulomas, aiding in the differentiation from inactive scars and monitoring treatment response in complex cases.^[117]^[118] Serological tests, including interferon-gamma release assays (IGRAs) like QuantiFERON-TB Gold, have limited utility for active MTBC diagnosis due to their focus on immune response rather than direct pathogen detection; however, they are effective for identifying latent tuberculosis infection, with sensitivities of 80-90% and specificities over 95% in low-prevalence populations. These assays measure T-cell release of interferon-gamma in response to MTBC-specific antigens, providing an alternative to tuberculin skin testing without cross-reactivity to BCG vaccination.^[119]^[120]

Treatment

Standard Regimens and First-Line Drugs

The first-line drugs for treating drug-susceptible infections caused by the Mycobacterium tuberculosis complex (MTBC) are isoniazid (INH), rifampin (RIF) or its analog rifapentine (RPT), pyrazinamide (PZA), and ethambutol (EMB). These agents target essential bacterial processes to achieve bactericidal and sterilizing effects. Isoniazid inhibits mycolic acid synthesis by forming a covalent adduct with the enoyl-acyl carrier protein reductase InhA, disrupting cell wall formation in actively replicating bacilli.^[121] Rifampin binds to the β-subunit of DNA-dependent RNA polymerase, inhibiting transcription initiation and elongation, which is crucial for killing both intracellular and extracellular organisms.^[122] Pyrazinamide, activated under acidic conditions within macrophages, disrupts membrane energetics, inhibits fatty acid synthase II, and interferes with ribosomal function and transport, preferentially affecting dormant persisters.^[123] Ethambutol blocks arabinosyltransferase enzymes (EmbA, EmbB, EmbC), preventing arabinogalactan polymerization and thus cell wall integrity.^[124] Current guidelines from the CDC and WHO recommend shorter regimens for non-severe, drug-susceptible pulmonary tuberculosis (TB) in eligible patients to improve adherence and outcomes.^[125]^[126] The preferred regimen for adults and adolescents (aged ≥12 years, weight ≥40 kg) without contraindications is a 4-month course: an intensive phase of 2 months with daily rifapentine (P), isoniazid (H), pyrazinamide (Z), and moxifloxacin (M; 2HPZM), followed by a 2-month continuation phase of once-weekly rifapentine, daily isoniazid, and moxifloxacin (2HPM). This regimen demonstrated noninferiority to the traditional 6-month standard, with treatment success rates of 84.6% in the phase 3 clinical trial (Study 31/A5349).^[127]^[128] For patients ineligible for the 4-month option (e.g., due to rifapentine intolerance or HIV with low CD4 counts), the alternative is the 6-month regimen: 2 months intensive phase (HRZE) followed by 4 months continuation (HR), totaling 6 months for most pulmonary cases.^[125] In children with non-severe TB, a 4-month HRZE regimen is recommended.^[125] These protocols apply post-confirmation of drug susceptibility, typically after 2 months of initial therapy. Monitoring for adverse effects is essential, as first-line drugs carry risks that can impact tolerability. Isoniazid commonly causes hepatotoxicity (elevated liver enzymes in up to 20% of patients, with severe injury in <1%), peripheral neuropathy (preventable with pyridoxine supplementation), and rash.^[129]^[130] Rifampin induces cytochrome P450 enzymes, leading to significant drug interactions (e.g., reducing efficacy of antiretrovirals or oral contraceptives), hepatotoxicity, and harmless orange discoloration of urine, tears, and sweat.^[129] Pyrazinamide is associated with hyperuricemia (in >80% of cases, potentially causing arthralgia or gout), hepatotoxicity, and gastrointestinal upset.^[129] Ethambutol primarily risks optic neuritis (dose-dependent, occurring in 1-5% at standard doses, manifesting as reduced visual acuity or color vision), necessitating baseline and monthly eye exams.^[131] Routine laboratory monitoring (liver function, uric acid, vision) and patient education mitigate these effects, with most resolving upon discontinuation.^[130] Adherence to the full regimen is critical to prevent treatment failure and resistance emergence. Directly observed therapy (DOT), where healthcare workers witness medication intake, is a cornerstone strategy, achieving treatment success rates exceeding 90% in high-burden settings when implemented comprehensively.^[132] In the U.S., 94% of TB cases involve at least partial DOT, contributing to overall cure rates >95% for drug-susceptible pulmonary TB upon completion.^[132] Digital alternatives like video-observed therapy support DOT in resource-limited areas, maintaining adherence without compromising efficacy.^[133]

Drug-Resistant Forms and Management

Drug-resistant forms of Mycobacterium tuberculosis complex (MTBC) pose significant challenges to tuberculosis (TB) control, primarily through multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid (INH) and rifampicin (RIF), the two most effective first-line drugs.^[134] Globally, an estimated 3.2% of new TB cases in 2023 were MDR-TB or rifampicin-resistant TB (MDR/RR-TB), affecting approximately 400,000 individuals that year (95% UI: 360,000–440,000).^[134] Extensively drug-resistant TB (XDR-TB) represents a more severe form, characterized by MDR/RR-TB plus resistance to any fluoroquinolone and at least one of bedaquiline or linezolid.^[135] Resistance in MTBC arises primarily from chromosomal mutations in genes encoding drug targets or activators, leading to either acquired resistance during suboptimal treatment or transmitted resistance via person-to-person spread.^[136] For INH, the most common mechanism involves mutations in the katG gene, particularly the Ser315Thr substitution, which impairs the enzyme's ability to activate the prodrug and confers high-level resistance.^[137] RIF resistance is predominantly due to mutations in the rpoB gene's rifamycin resistance-determining region, with alterations at codons 507-533 (e.g., Ser531Leu) disrupting RNA polymerase activity and accounting for over 95% of cases.^[136] These genetic changes reduce bacterial fitness but can be compensated by secondary mutations, facilitating transmission.^[138] Management of drug-resistant MTBC infections requires individualized, longer-duration regimens incorporating second-line drugs, guided by susceptibility testing and WHO/CDC recommendations updated in 2024/2025.^[139]^[140] Traditional MDR-TB treatment lasts 9-24 months and includes drugs like fluoroquinolones (e.g., levofloxacin), injectables (e.g., amikacin), and newer agents such as bedaquiline, which inhibits ATP synthase by binding to its subunit c, disrupting energy production in the bacterium.^[141] Delamanid, another key drug, targets mycolic acid biosynthesis by inhibiting the enzyme DesA1 after nitro-reduction to a reactive intermediate, weakening the cell wall.^[142] Linezolid contributes by binding to the 50S ribosomal subunit, halting protein synthesis essential for MTBC survival.^[143] For fluoroquinolone-susceptible MDR/RR-TB, the 2024 WHO guidelines endorse shorter all-oral regimens, such as a 6-month course of bedaquiline, pretomanid, and linezolid (BPaL) or a 6-month regimen including bedaquiline, delamanid, linezolid, levofloxacin, and clofazimine, achieving noninferior efficacy to longer protocols.^[140]^[144] In select cases with localized disease, surgical resection of affected lung tissue may be adjunctive to pharmacotherapy.^[139] Treatment outcomes for drug-resistant MTBC remain suboptimal, with global success rates for MDR/RR-TB reaching 68% for the 2021 treatment cohort (latest available data as of 2024), though only 44% of estimated cases accessed care.^[139] XDR-TB outcomes are poorer, with success rates around 30-40% due to limited effective drugs and higher toxicity.^[145] Shorter regimens have improved tolerability and adherence, boosting cure rates to over 80% in trials for eligible patients.^[146]

Prevention and Control

Vaccination Strategies

The Bacille Calmette-Guérin (BCG) vaccine, derived from a live attenuated strain of Mycobacterium bovis, remains the cornerstone of tuberculosis (TB) vaccination strategies worldwide. It is routinely administered at birth to newborns in approximately 157 countries, primarily those with high TB incidence, to prevent severe forms of the disease such as miliary and meningeal TB in children. Clinical trials and meta-analyses have demonstrated that BCG provides about 70% efficacy against these severe childhood manifestations, though its protection against pulmonary TB in adults is substantially lower, ranging from 0% to 20%.^[147]^[148] BCG exerts its protective effects primarily through the induction of a Th1 immune response, involving CD4+ T cells that produce interferon-gamma and other cytokines to enhance macrophage activation against Mycobacterium tuberculosis. This response promotes early containment of infection in the lungs and dissemination prevention in young children. However, immunity induced by BCG typically wanes after 10 to 15 years, correlating with increased TB incidence in adolescents and adults, and the vaccine does not effectively prevent latent infection or reactivation from latency.^[149]^[150]^[148] Despite its widespread use, BCG has notable limitations. Efficacy varies significantly by geographic region, with lower protection observed in tropical and subtropical areas—potentially due to environmental factors like vitamin D levels or co-infections—compared to higher efficacy at latitudes farther from the equator. Additionally, BCG is contraindicated in infants with symptomatic HIV infection due to the risk of disseminated BCG disease, a severe complication arising from the live attenuated nature of the vaccine.^[151]^[152]^[153] Efforts to improve upon BCG have led to promising vaccine candidates. The M72/AS01E subunit vaccine, comprising a fusion protein of two M. tuberculosis antigens (Mtb32A and Mtb39A) adjuvanted with AS01E, demonstrated 50% efficacy in preventing active pulmonary TB among adolescents and adults with latent infection in a phase 2b trial. As of 2025, a phase 3 efficacy trial is ongoing across multiple high-burden countries, with enrollment completed but results pending regulatory review and potential approval. Another candidate, VPM1002, is a recombinant BCG strain engineered to express listeriolysin O and lack urease C, aiming for enhanced safety and immunogenicity; it has shown superior reactogenicity and immune responses compared to standard BCG in phase 2 trials, and phase 3 studies in newborns and household contacts have been completed, with results indicating approximately 17% efficacy against all microbiologically confirmed TB, lower than anticipated, and further evaluation ongoing.^[154]^[155]^[156]^[157] Vaccination policies prioritize BCG in high-TB-burden settings, where universal neonatal immunization is recommended by the World Health Organization to avert childhood mortality, despite its incomplete protection. In low-incidence countries, such as the United States and much of Western Europe, BCG is generally not used routinely due to minimal public health benefit and interference with TB diagnostic tests, though it may be offered selectively to high-risk groups like healthcare workers exposed to multidrug-resistant strains.^[158]^[147]^[159]

Public Health Interventions

Public health interventions for controlling the spread of the Mycobacterium tuberculosis complex (MTBC) encompass a range of strategies aimed at early detection, transmission prevention, treatment adherence, surveillance, and addressing underlying social determinants. These approaches are integral to global efforts like the World Health Organization's (WHO) End TB Strategy, which sets a milestone of detecting at least 90% of incident TB cases by 2025 to reduce incidence and mortality. The 2025 WHO Global TB Report notes that while some gains have been made, funding challenges threaten these milestones, with only a 29% reduction in deaths achieved compared to the 75% goal.^[160]^[161] Case detection relies on both active and passive methods, particularly targeting high-risk groups such as household contacts, people living with HIV, migrants, and those in congregate settings. Active case finding involves systematic screening through contact tracing, community outreach, and targeted testing in vulnerable populations, which has been shown to identify more cases than passive approaches reliant on individuals presenting with symptoms at health facilities. For instance, household and close contacts are systematically screened for active TB disease, while passive detection focuses on symptom-based screening in routine healthcare visits. These strategies are emphasized in WHO guidelines to bridge detection gaps in high-burden settings.^[162]^[163]^[164] Infection control measures in healthcare and community settings prioritize reducing airborne transmission through environmental and administrative controls. Key practices include ensuring adequate ventilation to dilute infectious particles, use of N95 respirators or equivalent masks by healthcare workers, and isolation of suspected or confirmed cases in airborne infection isolation rooms with negative pressure. Ultraviolet germicidal irradiation (UVGI) at 254 nm wavelength is employed to inactivate M. tuberculosis in air, often in combination with high-efficiency particulate air (HEPA) filtration, proving effective in high-risk environments like hospitals and prisons. These interventions, when implemented as part of a hierarchical control plan, significantly lower nosocomial transmission risks.^[165]^[166]^[167] Treatment programs emphasize directly observed treatment, short-course (DOTS), a cornerstone strategy introduced by WHO in 1994 and now integrated into national TB programs in over 180 countries. DOTS involves standardized short-course chemotherapy supervised by healthcare workers to ensure adherence, achieving cure rates of up to 95% in compliant settings. To address adherence challenges, digital adherence technologies (DATs) such as video-observed therapy, electronic pill monitors, and mobile reminders have been increasingly adopted, with studies demonstrating improved treatment completion rates in resource-limited areas. These tools reduce the burden on patients and providers while supporting the expansion of community-based care.^[168]^[169] Surveillance systems form the backbone of monitoring MTBC transmission and intervention effectiveness, with national TB programs required to report case data annually to WHO through the Global Tuberculosis Report. This enables tracking of incidence, treatment outcomes, and drug resistance patterns globally. Genomic surveillance, leveraging whole-genome sequencing of M. tuberculosis isolates, has emerged as a critical tool for detecting outbreaks, identifying transmission clusters, and informing targeted responses, as outlined in WHO's global genomic surveillance strategy for pathogens with pandemic potential. In the United States, for example, molecular surveillance identified 1,110 TB clusters from 2021–2023, aiding in outbreak investigations.^[170]^[171] Social measures target structural drivers of MTBC transmission, including poverty, migration, and zoonotic risks from M. bovis. Interventions to alleviate poverty, such as cash transfers and nutritional support for TB-affected households, interrupt the cycle of vulnerability by reducing food insecurity and catastrophic costs, which affect 13% to 92% of patients and households in low- and middle-income countries, often around 50% in national surveys. For migrant populations, community-based strategies like mobile clinics and culturally sensitive screening address barriers to care exacerbated by displacement and socioeconomic marginalization. A One Health approach integrates human, animal, and environmental health to control zoonotic TB from M. bovis, emphasizing pasteurization of milk, bovine surveillance, and cross-sectoral collaboration to prevent spillover, particularly in regions with high livestock-human interface.^[172]^[173]^[174]^[175]

History and Future Directions

Historical Discovery and Milestones

The discovery of the Mycobacterium tuberculosis complex (MTBC) began with the identification of its primary human pathogen. In 1882, German physician Robert Koch isolated and cultured the tubercle bacillus from the lungs of patients with tuberculosis (TB), announcing his findings on March 24 to the Physiological Society of Berlin and publishing a seminal paper that established it as the causative agent of the disease, known thereafter as "Koch's bacillus."^[176]^[177] This breakthrough fulfilled key postulates of Koch's criteria for proving microbial causation and marked a pivotal moment in microbiology.^[178] For his contributions to understanding TB and other infectious diseases, Koch received the Nobel Prize in Physiology or Medicine in 1905.^[178] In the early 20th century, efforts to control TB focused on preventive and supportive measures amid limited therapeutic options. French scientists Albert Calmette and Camille Guérin developed the bacillus Calmette-Guérin (BCG) vaccine through 230 serial passages of a virulent Mycobacterium bovis strain, rendering it attenuated; the first human administration occurred in 1921 to an infant in Paris.^[179]^[180] Concurrently, sanatoria emerged as a cornerstone of TB management, emphasizing fresh air, rest, and isolation; by the early 1900s, these institutions proliferated worldwide, with the United States alone operating over 600 by 1925 to house patients in controlled environments.^[180]^[181] Recognition of zoonotic transmission within the MTBC grew when Koch identified M. bovis as a distinct bovine pathogen in 1904, demonstrating its ability to infect humans via unpasteurized milk, which prompted public health measures like mandatory pasteurization starting in the early 1900s to curb milk-borne cases.^[182]^[183] The mid-20th century ushered in the antibiotic era, transforming TB from a largely fatal condition to a treatable one. In 1944, Selman Waksman and colleagues isolated streptomycin from Streptomyces griseus, marking the first effective chemotherapeutic agent against TB; clinical trials demonstrated its ability to sterilize pulmonary lesions, though resistance emerged quickly.^[184]^[185] By 1952, isoniazid (INH), synthesized from nicotinic acid derivatives, became available as a highly potent, oral bactericidal drug that enabled shorter inpatient stays and outpatient therapy, drastically reducing mortality rates when combined with streptomycin and para-aminosalicylic acid.^[185]^[186] Key global milestones in the late 20th and early 21st centuries addressed diagnostics and treatment challenges. In 1993, the World Health Organization (WHO) declared TB a global emergency, galvanizing international coordination through the Directly Observed Treatment, Short-course (DOTS) strategy to combat resurgence driven by HIV and resistance.^[187] In 2010, WHO endorsed the Xpert MTB/RIF assay, a rapid molecular test for detecting MTBC DNA and rifampicin resistance in under two hours from sputum, revolutionizing diagnosis in resource-limited settings.^[188] The 2020s saw advancements in regimen optimization, with WHO and partners recommending shorter all-oral treatments, such as a 4-month regimen for drug-susceptible pulmonary TB in eligible patients using rifapentine, moxifloxacin, isoniazid, and pyrazinamide, as per guidelines updated in January 2025, and 6-month BPaL (bedaquiline, pretomanid, linezolid) for multidrug-resistant forms, based on trials showing noninferiority to longer standards.^[189]^[190]^[191] In January 2025, the American Thoracic Society, CDC, European Respiratory Society, and IDSA jointly endorsed expanded use of shorter 4-month regimens for drug-susceptible TB in eligible children, adolescents, and adults.^[189]

Ongoing Research and Challenges

Ongoing research into the Mycobacterium tuberculosis complex (MTBC) focuses on overcoming persistent barriers to eradication, including vaccine efficacy, treatment duration, and understanding latency mechanisms. Recent advances in vaccine development have centered on subunit candidates like M72/AS01E, which demonstrated 50% efficacy in preventing active pulmonary tuberculosis among HIV-negative adolescents and adults in a Phase 2b trial conducted across high-burden countries in Africa, with results published in 2020. A Phase 3 trial involving over 26,000 participants was initiated in 2024 and is ongoing as of 2025.^[154] This trial marked a significant step forward, as it is the first new TB vaccine candidate to advance to Phase 3 in over a century to potentially show protective efficacy, though it did not prevent infection itself in earlier studies. Complementing these efforts, CRISPR-Cas9 technologies are being explored to engineer novel vaccine candidates by precisely editing MTBC antigens for enhanced immunogenicity, with preclinical studies showing improved T-cell responses in animal models. In drug discovery, the BPaL regimen—comprising bedaquiline, pretomanid, and linezolid—received accelerated FDA approval on August 14, 2019, for treating extensively drug-resistant (XDR) and treatment-intolerant multidrug-resistant (MDR) TB, reducing treatment duration to six months from the traditional 18–24 months while achieving 89% success rates in Phase 3 trials. This all-oral, shorter regimen addresses adherence challenges but requires monitoring for linezolid-related toxicities like peripheral neuropathy. Parallel research into host-directed therapies (HDTs) targets excessive inflammation to improve outcomes, with agents like metformin showing promise in Phase 2 trials by modulating immune responses and reducing lung damage in adjunctive use with standard antibiotics. Studies on latency and persistence emphasize modeling dormancy to identify intervention points. Zebrafish (Danio rerio) have emerged as a key non-mammalian model for visualizing granuloma formation and bacterial persistence, revealing hypoxic niches that mimic human latent TB infection and informing drug screening for sterilizing activity. Efforts to develop biomarkers for reactivation risk include interferon-gamma inducible protein 10 (IP-10) and other host-derived signatures, which in longitudinal cohorts predict progression from latent to active disease with up to 80% accuracy, enabling targeted preventive therapy. Major challenges persist, particularly diagnostic gaps in low-resource settings where rapid tests like Xpert MTB/RIF are underutilized due to cost and infrastructure limitations, leading to delayed detection and ongoing transmission. Global consortia, such as the Critical Path to TB Drug Regimens (CPTR) initiative and RePORT International, facilitate real-time genomic surveillance of antimicrobial resistance, tracking MTBC lineages and mutations to guide policy, though data-sharing inequities hinder comprehensive monitoring. Emerging evidence also links climate change to altered TB transmission dynamics, with rising temperatures and extreme weather exacerbating migration and crowding in endemic areas. Future directions include leveraging artificial intelligence for outbreak prediction, where machine learning models integrated with genomic and epidemiological data have forecasted local epidemics with 85% precision in pilot studies from South Africa and India. Additionally, research toward a universal TB vaccine aims to protect all age groups, including infants and the elderly, through pan-MTBC antigens and adjuvants, with candidates like MTBVAC in Phase 3 trials showing broad immunogenicity across demographics.

References

[1]
Tuberculosis Overview - StatPearls - NCBI Bookshelf
Mycobacterium tuberculosis, the causative agent of TB, has plagued humanity for millennia. Diagnostic approaches include the Mantoux skin test and the ...Introduction · Pathophysiology · Evaluation · Treatment / Management
[2]
Virulence factors of the Mycobacterium tuberculosis complex - PMC
The Mycobacterium tuberculosis complex (MTBC) consists of closely related species that cause tuberculosis in both humans and animals.
[3]
Clinical Overview of Tuberculosis - CDC
Jan 6, 2025 · TB bacteria usually attack the lungs but can attack any part of the body such as the kidney, spine, and brain. TB can also affect multiple parts ...
[4]
Insights from the 2024 WHO Global Tuberculosis Report – More ...
Dec 2, 2024 · The 2024 WHO Global TB Report highlights the return of tuberculosis (TB), caused by Mycobacterium tuberculosis, as the leading infectious killer posing ...
[5]
Global tuberculosis report 2024 - World Health Organization (WHO)
Oct 29, 2024 · In 2024, 193 countries and areas (out of 215) with more than 99% of the world's population and TB cases reported data.
[6]
A new evolutionary scenario for the Mycobacterium tuberculosis ...
The mycobacteria grouped in the Mycobacterium tuberculosis complex are characterized by 99.9% similarity at the nucleotide level and identical 16S rRNA ...
[7]
A Comprehensive Map of Mycobacterium tuberculosis Complex ...
The members of the complex include the following Mycobacterium species: M. africanum (i.e., MTBC lineage 5 and lineage 6) (2), M.
[8]
About Bovine Tuberculosis in Humans - CDC
May 20, 2024 · Unpasteurized dairy products. People are most commonly infected with M. bovis by eating or drinking contaminated, unpasteurized dairy products.
[9]
Origin, Spread and Demography of the Mycobacterium tuberculosis ...
Sep 26, 2008 · In this study, we provide genetic evidence indicating that the most common ancestor of the bacterial complex emerged some 40,000 years ago from ...Missing: 40000-70000 | Show results with:40000-70000
[10]
A new evolutionary scenario for the Mycobacterium tuberculosis ...
This observation suggests that the common ancestor of the tubercle bacilli resembled M. tuberculosis or M. canettii and could well have been a human pathogen ...Missing: East Africa 40000-70000
[11]
Co‐evolution of Mycobacterium tuberculosis and Homo sapiens
Feb 20, 2015 · Unlike postulated until a decade ago, it is now clear that humans did most likely not acquire the tubercle bacilli from cattle during animal ...
[12]
Evolutionary analysis of Mycobacterium bovis genotypes across ...
Mar 2, 2020 · The genetic coalescence of M. bovis have been estimated to at least around 6000 years [15] and domesticated cattle existed along humans in ...
[13]
Determination of Major Lineages of Mycobacterium tuberculosis ...
We present a novel Bayesian network (BN) to classify strains of Mycobacterium tuberculosis Complex (MTBC) into six major genetic lineages.
[14]
After the bottleneck: Genome-wide diversification of the ... - NIH
To perform a genome-scale analysis of how genetic diversity builds up in the lineages, we analyzed the SNPs of the genomes of 24 MTBC strains from all major ...
[15]
Diversity of Mycobacterium tuberculosis across Evolutionary Scales
We find that the amount of M.tb genetic diversity harbored by individuals with TB can vary dramatically, likely as a function of disease severity.
[16]
Novel methods included in SpolLineages tool for fast and precise ...
Dec 15, 2020 · Several software tools allow to predict MTBC genotyping families from spoligotyping and/or MIRU-VNTR patterns; examples include the following ...
[17]
Mycobacterium tuberculosis complex DNA from an extinct bison ...
Mycobacterium tuberculosis complex DNA from an extinct bison dated 17,000 years before the present. Clin Infect Dis. 2001 Aug 1;33(3):305-11. doi: 10.1086 ...Missing: 18000 old medieval human skeletons
[18]
Genotypic analysis of Mycobacterium tuberculosis from medieval ...
Three medieval bone samples with osteological evidence of tuberculosis infection were analysed for the presence of DNA sequences from Mycobacterium tuberculosis ...Missing: 18000 year old bison
[19]
Insights into the ancestry evolution of the Mycobacterium ...
Aug 11, 2021 · In contrast, the MTBC species have lost genes involved in free-living survival due to their obligate pathogen lifestyle. We compared the 79 ...Materials And Methods · Results · M. Riyadhense Strains...
[20]
Key Transitions in the Evolution of Rapid and Slow Growing ...
Jan 20, 2020 · Mycobacteria have been classified into rapid and slow growing phenotypes, but the genetic factors that underlie these growth rate differences are not well ...Missing: MTBC | Show results with:MTBC
[21]
Tuberculosis (TB): Background, Pathophysiology, Etiology
Oct 31, 2024 · Mtb are non-spore-forming and nonmotile curved intracellular rods measuring 0.2-0.5 μm by 2-4 μm. Their cell walls contain mycolic acid-rich ...
[22]
Tuberculosis (TB) | Office of Research Safety
The bacteria that cause tuberculosis (TB) are acid-fast (stain Gram positive), aerobic, non-spore forming, non-motile bacteria. Forming slightly curved or ...
[23]
[PDF] Acid-Fast Stain Protocols - American Society for Microbiology
Sep 8, 2008 · The cell walls of the mycobacteria contain mycolic acids giving the cell walls a high lipid content. This characteristic is thought to be the ...
[24]
The Mycobacterial Cell Wall—Peptidoglycan and Arabinogalactan
The mycolyl-arabinogalactan-peptidoglycan (mAGP) complex is essential for the viability of Mycobacterium tuberculosis and maintains a robust basal structure ...
[25]
Assembly of the Mycobacterial Cell Wall - Annual Reviews
Oct 15, 2015 · M. tuberculosis possesses an unusual cell wall dominated by lipids and carbohydrates that provides a permeability barrier against hydrophilic ...Missing: composition | Show results with:composition<|separator|>
[26]
The thick waxy coat of mycobacteria, a protective layer against ...
May 29, 2020 · The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host's immune system - PMC.
[27]
Mycobacterium tuberculosis: Properties of the Bacteria - BrainKart
Jul 21, 2017 · M. tuberculosis is an obligate aerobe and characteristically growsvery slowly in media. Optimum temperature is 37°C, and the bacteria do not ...
[28]
Physiology of Mycobacteria - PMC - PubMed Central - NIH
Mycobacterial cells are irregular rods 0.3–0.5 μm in diameter and of variable length (Wayne and Kubica, 1986). The images of cells of M. smegmatis shown in Fig.
[29]
Löwenstein-Jensen Medium - an overview | ScienceDirect Topics
MTBC colonies are characteristically dry with a rough texture and a cream/tan color, and are colloquially described as “rough and buff.” Conversely, M.
[30]
Mycobacterium tuberculosis Metabolism - PMC - PubMed Central
This review provides a broad summary of mycobacterial metabolism, highlighting the adaptation of M. tuberculosis as specialist human pathogen.Missing: traits niacin catalase
[31]
Niacin production test for MTB - Knowledge Base
Cultures grown on egg medium containing Asparagine yield the most consistent results in the niacin test, and LJ medium is therefore recommended.
[32]
Mycobacteriosis and Tuberculosis: Laboratory Diagnosis - PMC - NIH
Mar 30, 2018 · 68 degree Celsius Catalase Test. The test is positive for only a few of mycobacteria which their catalase enzyme can resist to being heated ...
[33]
https://ntep.in/node/3983/CP-niacin-production-test-mtb
[34]
Chemical Disinfectants | Infection Control | CDC
Nov 28, 2023 · Higher concentrations (1,000 ppm) of chlorine are required to kill M. tuberculosis using the Association of Official Analytical Chemists (AOAC) ...
[35]
Deciphering the biology of Mycobacterium tuberculosis from the ...
Jun 11, 1998 · The genome comprises 4,411,529 base pairs, contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in the ...
[36]
Mycobacterium bovis: From Genotyping to Genome Sequencing
MTBC genomes are highly similar, with >99.95% identity over homologous nucleotide sequences, including the ribosomal RNA genes, while horizontal gene ...
[37]
Infect and Inject: How Mycobacterium tuberculosis Exploits Its Major ...
The deleted region is called region of difference 1 (RD1), and it encodes a key part of the type VII secretion system known as ESAT-6 secretion system 1 (ESX-1) ...
[38]
In-depth Analysis of IS6110 Genomic Variability in the ... - NIH
Feb 24, 2022 · The insertion sequence (IS) 6110 is a repetitive mobile element specific for the Mycobacterium tuberculosis complex (MTBC) used for years to ...
[39]
The Mycobacterium tuberculosis complex pangenome is small and ...
Sep 5, 2025 · This useful study analyzed 335 Mycobacterium tuberculosis Complex genomes and found that MTBC has a closed pangenome with few accessory ...
[40]
The Mycobacterium tuberculosis DosR Regulon Assists in Metabolic ...
The DosR regulon is a set of at least 48 coregulated genes that are induced by three conditions that inhibit aerobic respiration: hypoxia, NO, and CO (42).
[41]
Naming spoligotype patterns for the RD9-deleted lineage of the ...
The purpose of the website is to provide standardised names for spoligotype patterns from strains of the RD9-deleted, lineage of the Mycobacterium tuberculosis ...
[42]
Leveraging large-scale Mycobacterium tuberculosis whole genome ...
Nov 7, 2024 · Whilst many DR mutations in the Mtb genome are known, analysis of large datasets generated using whole genome sequencing (WGS) platforms can ...
[43]
[PDF] Issues in Mycobacterium tuberculosis Complex Drug Susceptibility ...
The primary mechanism of PZA resistance is due to mutations in the pncA gene and promoter region. • PZA growth-based DST using automated broth systems have ...<|control11|><|separator|>
[44]
Mycobacterium tuberculosis: The Mechanism of Pathogenicity ...
Nov 26, 2024 · The bacilli then migrate to the lower respiratory tract, where they invade the alveoli and are engulfed by alveolar macrophages and other ...
[45]
Macrophages in Tuberculosis: Friend or Foe - PMC - PubMed Central
... Mycobacterium tuberculosis (Mtb) is acquired by the respiratory route. It is exquisitely human-adapted and a prototypic intracellular pathogen of macrophages ...
[46]
Macrophage Receptors for Mycobacterium tuberculosis - PMC - NIH
This review summarizes recent studies of macrophage receptors involved in the uptake of Mycobacterium tuberculosis as well as the current state of knowledge of ...
[47]
ESX-1 dependent impairment of autophagic flux by Mycobacterium ...
We found that Mtb H37Rv impairs autophagy at the step of autophagosome-lysosome fusion. In contrast, neither Mtb H37Ra nor BCG strains were able to hamper ...
[48]
Manipulation of the endocytic pathway and phagocyte functions by ...
Lipoarabinomannan is a major immunomodulatory lipoglycan found in the cell envelope of Mycobacterium tuberculosis and related human pathogens.
[49]
Trehalose 6,6′-Dimycolate (Cord Factor) of Mycobacterium ... - NIH
Cord factor (trehalose 6,6′-dimycolate [TDM]), a surface glycolipid, causes M. tuberculosis to grow in serpentine cords in vitro. Virulent strains of M.
[50]
Disruption of the Genes Encoding Antigen 85A and Antigen 85B of ...
These proteins have recently been shown to possess mycolyl transferase activity and likely play a role in cell wall synthesis. The purpose of this study was to ...
[51]
The Tuberculous Granuloma: An Unsuccessful Host Defence ...
Caseous granulomas are typical of tuberculosis. These structures are formed by epithelioid macrophages surrounding a cellular necrotic region with a rim of ...
[52]
Mycobacterium tuberculosis Dissemination Plays a Critical Role in ...
Feb 25, 2020 · Infecting animals with very low doses of M. tuberculosis results in the formation of a small number of granulomas that eventually become large ...
[53]
Challenging Mycobacterium tuberculosis dormancy mechanisms ...
Sep 8, 2015 · Though strictly aerobic, M. tuberculosis may face low oxygen levels during the course of infection, typically in late granulomas, which are ...
[54]
Innate immunity in tuberculosis: host defense vs pathogen evasion
The major innate immune cell types involved in tuberculosis (TB) infection are macrophages, dendritic cells (DCs), neutrophils and natural killer (NK) cells.
[55]
Innate and Adaptive Cellular Immune Responses to Mycobacterium ...
Host resistance to Mycobacterium tuberculosis (Mtb) infection requires the coordinated efforts of innate and adaptive immune cells.
[56]
Host Immune Response to Mycobacterium tuberculosis Infection
Jun 27, 2025 · The innate immune system serves as the body's first line of defense against Mtb, playing a crucial role in the early response to the pathogen.
[57]
Role of MHC class I pathways in Mycobacterium tuberculosis ...
Mar 15, 2023 · This review looks at the MHC-I antigen processing pathway and potential alternative sources of the antigens, focusing on Mycobacterium tuberculosis (Mtb)
[58]
Latent Tuberculosis: Models, Computational Efforts and the ...
We review studies that give insights into latency/dormancy regulatory mechanisms that enable infection persistence and pathogen adaptation to different stress ...
[59]
The DosR regulon of M. tuberculosis and antibacterial tolerance - PMC
Jul 3, 2009 · Activated DosR initiates transcription of a set of genes known as the DosR regulon, which allow the bacteria to survive long periods of ...
[60]
Regulation of antigen presentation by Mycobacterium tuberculosis
Immune evasion allows M. tuberculosis to establish persistent or latent infection in macrophages and results in Toll-like receptor 2 (TLR2)-dependent inhibition ...<|control11|><|separator|>
[61]
Intelligent Mechanisms of Macrophage Apoptosis Subversion ... - NIH
Mar 16, 2020 · Here, we describe the intelligent strategies of Mtb inhibition of macrophages apoptosis. This review provides a platform for the future study.
[62]
The Immune Escape Mechanisms of Mycobacterium Tuberculosis
Jan 15, 2019 · Mycobacterium tuberculosis (MTB) is an intracellular parasite that mainly attacks macrophages and inhibits their apoptosis.
[63]
SLC11A1 (NRAMP1) Polymorphisms and Tuberculosis Susceptibility
Jan 25, 2011 · Our results suggested a consistent association between SLC11A1 polymorphisms and TB in different populations, which supports the hypothesis that ...
[64]
Host genetics and tuberculosis: Theory of genetic polymorphism and ...
There was evidence of the association between SLC11A1 polymorphisms and TB susceptibility, supporting the hypothesis that NRAMP-1 (SLC11A1) gene might play on ...
[65]
The Research Progress of Host Genes and Tuberculosis Susceptibility
Several other studies have also pointed out that the SLC11A1 gene not only is associated with TB susceptibility and progression of pulmonary TB but may also ...
[66]
Tuberculosis in Children - StatPearls - NCBI Bookshelf
Nov 22, 2024 · Nonspecific symptoms, such as flu-like illness, low-grade fever, malaise, and pulmonary symptoms, may overshadow central nervous system findings ...
[67]
Clinical Manifestations - Tuberculosis in Adults and Children - NCBI
A primary (Ghon) complex is formed, consisting of a granuloma, typically in the middle or lower zones of the lung (primary or Ghon focus) in combination with ...Tuberculosis In Adults And... · Chapter 3clinical... · 3.3. 1. Pleural Tuberculosis
[68]
Clinical Overview of Latent Tuberculosis Infection - CDC
Apr 17, 2025 · ... 5%–10% of infected people will develop TB disease over their lifetimes. People with latent TB infection are at risk for TB disease.
[69]
Epidemiology and factors associated with Extra-pulmonary ... - NIH
Pulmonary tuberculosis (PTB) is the most frequent clinical manifestation of the disease, accounting for 85% of reported TB cases worldwide. When TB affects any ...
[70]
A Spotlight on Liquefaction: Evidence from Clinical Settings and ...
Mar 13, 2011 · The impact of a high oxygen pressure in promoting TB has been recently epidemiologically demonstrated by the description of a lower TB incidence ...
[71]
Miliary Tuberculosis - StatPearls - NCBI Bookshelf - NIH
Jan 30, 2024 · Miliary TB is a potentially fatal form of disseminated TB characterized by millet-seed-like granuloma formation in various organs. Miliary ...Continuing Education Activity · Introduction · History and Physical · Evaluation
[72]
Tuberculosis and lung damage: from epidemiology to pathophysiology
Pulmonary cavitation may obliterate or distort airways, leading to airflow obstruction. In a study of serial changes in lung structure and pulmonary function, ...
[73]
Pulmonary function and respiratory health after successful treatment ...
In linear regression, age, prior TB, and CXR fibrosis or bronchiectasis were significantly associated with decreased pulmonary function.
[74]
Risk Factors of Tuberculosis Destroyed Lung in Patients with ... - NIH
Mar 28, 2024 · These complications collectively diminish pulmonary function, potentially leading to respiratory failure or death by suffocation. Limitation.
[75]
Epidemiology of Extrapulmonary and Disseminated Tuberculosis
The most common sites of infection in the EPTB group were the lymph nodes (42%), the abdomen (31%), brain (10%), musculoskeletal tissue (10%), and other sites ( ...
[76]
Tuberculosis (TB) Clinical Presentation: History, Physical Examination
Oct 31, 2024 · Generalized lymphadenopathy can be seen in 35% of extrapulmonary TB cases. The typical presentation includes painless swelling of cervical and ...History · Pulmonary Tb · Tuberculous Meningitis
[77]
2.2 Extrapulmonary tuberculosis - MSF Medical Guidelines
Active TB can develop in many other parts of the body, particularly in lymph nodes, meninges, bones and joints, kidneys, genital organs and the abdominal cavity ...2.2. 2 Tuberculous... · 2.2. 3 Tuberculosis Of Bones... · 2.2. 6 Tuberculous Pleural...Missing: genitourinary | Show results with:genitourinary
[78]
Genitourinary Tuberculosis - StatPearls - NCBI Bookshelf - NIH
Aug 16, 2024 · The lymph nodes, pleura, urogenital tract, abdominal, bones/joints, and meninges are the most commonly affected extrapulmonary tuberculosis ...
[79]
[PDF] Mycobacterium bovis Disease in Humans
Jul 8, 2021 · bovis caused extrapulmonary TB in people. – Increased risk of cervical lymphadenitis in children who drank cow's milk. Page 6. Evolution of M.
[80]
Site of Extrapulmonary Tuberculosis is Associated with HIV Infection
Among patients hospitalized with EPTB, patients coinfected with HIV and low CD4 counts were more likely to have CNS/meningeal and disseminated disease.Missing: bovis abdominal
[81]
Risk factors for extrapulmonary dissemination of tuberculosis and ...
Jun 6, 2018 · Many environmental, host, and microbial characteristics have been recognized as risk factors for dissemination of extrapulmonary tuberculosis (EPTB).
[82]
Central Nervous System Tuberculosis: Risk Factors for Mortality in a ...
Unfortunately, CNS-TB is associated with high mortality rates (10%–20%) and can result in disabling neurological complications (5%–24%) [1, 4, 6, 10, 11].
[83]
1.1 TB incidence - World Health Organization (WHO)
An estimated global total of 10.8 million people (95% uncertainty interval [UI]: 10.1–11.7 million) fell ill with TB in 2023, equivalent to 134 incident cases.1.4 National TB prevalence... · 1.2 TB mortality · 1.3 Drug-resistant TB
[84]
1.2 TB mortality - World Health Organization (WHO)
In 2023, most of the estimated deaths caused by TB among HIV-negative people occurred in the WHO regions of South-East Asia (54%) and Africa (27%), with smaller ...
[85]
Tuberculosis surveillance and monitoring in Europe 2025 - 2023 data
Mar 24, 2025 · In 2023, 38 993 cases of TB were reported in 29 European Union and European Economic Area (EU/ EEA) countries, resulting in a notification rate of 8.6 per 100 ...Missing: Western | Show results with:Western
[86]
5.2 Costs faced by TB-affected households, social protection and ...
The average total cost per TB episode incurred by TB-affected households ranged from US$ 76 (95% confidence interval [CI]: US$ 60–94) in the Gambia to US$ 3700 ...
[87]
5 Financing for tb prevention diagnostic and treatment services
... 13 billion per year for TB prevention, diagnostic and treatment services ... Domestic and donor financing for tuberculosis care and control in low-income ...
[88]
Tuberculosis Infectiousness and Host Susceptibility - PubMed Central
Tuberculosis is the archetype of airborne-transmitted infectious diseases, with Mycobacterium tuberculosis serving as the causative agent [1]. For human ...
[89]
Mycobacterium tuberculosis Transmission in High-Incidence ... - NIH
M. tuberculosis is considered the archetypical example of aerosol transmission through small airborne particles (<5 µm) that remain suspended in the air and ' ...
[90]
Pathogen Safety Data Sheets: Infectious Substances - Canada.ca
These bacteria are acid-fast, aerobic, non-spore forming, non-motile bacteria (Footnote 1) . They form slightly curved or straight rods which may branch.
[91]
Secondary Attack Rate of Tuberculosis in Urban Households in ...
The overall secondary attack rate for tuberculosis infection was 47.4 (95% confidence interval: 44.3, 50.6) and did not vary widely with age, HIV status or BCG ...
[92]
Exposure to Tuberculosis - CDC
Mar 25, 2024 · People with active TB disease are most likely to spread it to people they spend time with every day. This includes family members, friends, and ...
[93]
Guidelines for Preventing the Transmission of Tuberculosis in ... - CDC
The most infectious persons are those with pulmonary or laryngeal tuberculosis. Those with extrapulmonary tuberculosis are usually not infectious, with the ...
[94]
How much do smear-negative patients really contribute to ...
Previous estimates that smear-negative patients contribute 13–20% of transmissions and are, on average, 20 to 25% as infectious as smear-positive cases are ...
[95]
Upper-Room Ultraviolet Light and Negative Air Ionization to Prevent ...
Mar 17, 2009 · Upper-room UV lights, combined with adequate air mixing, or negative air ionization with special large-scale ionizers can prevent most airborne tuberculosis ...
[96]
Quantifying TB transmission: a systematic review of reproduction ...
The reproductive number estimates ranged from 0.24 in the Netherlands (during 1933–2007) to 4.3 in China in 2012. We found a limited number of publications and ...Missing: 2.5-3 | Show results with:2.5-3
[97]
Risk Factors for Tuberculosis - PMC - PubMed Central
Along with well-established risk factors (such as human immunodeficiency virus (HIV), malnutrition, and young age), emerging variables such as diabetes, indoor ...
[98]
Risk factors for tuberculosis: diabetes, smoking, alcohol use ... - NIH
One recent study showed that smoking and HIV infection were significant risk factors for mortality in patients with MDR-TB. When smokers quit smoking, the risk ...
[99]
Revisiting the timetable of tuberculosis - The BMJ
Aug 23, 2018 · Reactivation TB is thought to occur most frequently later in life when immunity wanes or intercurrent illness occurs. If this were the case, we ...
[100]
Systematic Review of Knowledge, Attitudes, and Practices of Dairy ...
Apr 19, 2024 · Human tuberculosis is caused by Mycobacterium tuberculosis (2) but up to 10% of human cases are caused by Mycobacterium bovis (M. bovis) ...
[101]
Milk and meat consumption patterns and the potential risk of ...
... 10–15% of all human TB cases are caused by M. bovis [21]. Although such high rates of zoonotic transmission may exist in certain contexts and under certain ...
[102]
Clinical and Laboratory Diagnosis for Tuberculosis - CDC
Jan 31, 2025 · Culturing the specimen means growing the mycobacteria on solid or in liquid media. All specimens should be cultured, regardless of whether the ...
[103]
[DOC] Selective Culture Use, Specimen Collection & Processing
The mucolytic agent N-acetyl L-cysteine (NALC) enables the decontaminating agent, sodium hydroxide, to be used at a lower final concentration. Sodium ...
[104]
[PDF] PDF - CDC
After samples were decontaminated by sodium hydrox- ide (NaOH) in N-acetyl-L-cysteine-sodium hydroxide. (NALC-NaOH method) (6), cultures were done on solid.
[105]
A Minimum 5.0 ml of Sputum Improves the Sensitivity of Acid-fast ...
Aug 17, 1999 · Sputum acid-fast smears have a sensitivity of approximately 45 to 75% for Mycobacterium tuberculosis recovered by growth in culture (3-6). When ...
[106]
Acid Fast Bacteria - StatPearls - NCBI Bookshelf
Aug 7, 2023 · AFB-microscopy is indicated for suspected cases of tuberculosis. Positive microscopy confirms the presence of acid-fast bacilli. Care must be ...<|separator|>
[107]
Comparison of Mycobacterium tuberculosis complex Yield and ...
While molecular methods have been recently endorsed for diagnosis of tuberculosis (TB), mycobacterial culture remains the gold standard. Lowenstein-Jensen (LJ) ...
[108]
Methods of phenotypic identification of non-tuberculous mycobacteria
Niacin accumulation test ... Measure the column of bubbles. •. Interpretation: ➢. For thermo-stable catalase: evolution of bubbles indicate a positive test.
[109]
[PDF] Biosafety in Microbiological and Biomedical Laboratories—6th Edition
We wish to emphasize that the sixth edition of BMBL remains an advisory document recommending best practices for the safe conduct of work in biomedical and ...
[110]
Xpert MTB/RIF assay for the diagnosis of pulmonary and ...
WHO's current policies and guidance recommend that Xpert MTB/RIF be used as an initial diagnostic test in individuals suspected of having MDR-TB or HIV- ...
[111]
Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis
The pooled Xpert MTB/RIF sensitivity was 85% (95%CI, 70–93%) and specificity was 98% (95%CI, 97–99%) with negative likelihood ratio of 0.15 (95%CI, 0.04–0.27) ...Eligible Studies · Risk Of Bias Assessment · Figure 2<|control11|><|separator|>
[112]
Line probe assays for detection of drug-resistant tuberculosis
May 13, 2022 · This document was developed to provide practical guidance on interpretation of the most commonly used first- and second-line line probe assays (LPAs).
[113]
Catalogue of mutations in Mycobacterium tuberculosis complex and ...
Nov 15, 2023 · This 2023 update includes the analysis of over 52 000 isolates with matched data on whole genome sequencing and phenotypic drug susceptibility ...
[114]
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and ...
Jan 11, 2017 · Chest radiographs are used to stratify for risk and to assess for asymptomatic active disease. Sequelae of previous tuberculosis that is now ...
[115]
FDG-PET-CT as an early detection method for tuberculosis
Jul 29, 2024 · This meta-analysis discusses the current literature, including the methods, results and implications of using FDG-PET-CT in the early diagnosis of TB.
[116]
Use of alternative interferon-gamma release assays for the ...
Jan 28, 2022 · Two classes of tests – tuberculin skin test (TST) and interferon-gamma release assay (IGRA) – are currently recommended by WHO to test for TB infection.
[117]
Clinical Testing Guidance for Tuberculosis: Interferon Gamma ... - CDC
May 9, 2024 · TB blood tests (interferon-gamma release assay or IGRA) are methods of determining whether a person is infected with TB bacteria.
[118]
Tuberculosis Drugs and Mechanisms of Action | NIAID
Apr 19, 2016 · Isoniazid, Rifampin, Ethambutol and Pyrazinamide are the first-line of treatment of drug. Shown here are the four drugs in the standard regimen ...
[119]
Rifampin: Uses, Interactions, Mechanism of Action | DrugBank Online
Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).Pharmacology · Products · Categories · References<|separator|>
[120]
The molecular basis of resistance to isoniazid, rifampin, and ...
Apr 5, 2001 · The present review gives a concise summary of the mechanism of action and the molecular basis of resistance to isoniazid, rifampin, and pyrazinamide.
[121]
Treatment of Sensitive Tuberculosis: Mechanisms of Action and ...
Jun 4, 2019 · A review of the mechanisms of action of first-line drugs used in the treatment regimen to sensitive tuberculosis, as well as the main associated resistance ...
[122]
Treatment for Drug-Susceptible Tuberculosis Disease - CDC
Apr 17, 2025 · The 4-month 2HPZM/2HPM TB treatment regimen consists of: Isoniazid (H),. Rifapentine (P),. Pyrazinamide (Z), and. Moxifloxacin (M).
[123]
Treatment of Drug-Resistant and Drug-Susceptible TB - IDSA
Dec 30, 2024 · New DS-TB recommendations include use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with non-severe TB.Summary of Recommendations · Introduction · Methods · Discussion
[124]
Adverse Events During TB Treatment | Tuberculosis (TB) - CDC
Apr 17, 2025 · Fever for 3 or more days • Flu-like symptoms • Lack of appetite • Nausea • Vomiting • Yellow skin or eyes, Serious. Isoniazid, Nervous system ...Missing: primary | Show results with:primary<|control11|><|separator|>
[125]
Clinical standards for the management of adverse effects during ...
Jul 1, 2023 · Use of first-line therapy for TB is associated with raised liver transaminases in about 20% of those treated, which spontaneously resolves over ...
[126]
Incidence of Serious Side Effects from First-Line Antituberculosis ...
Jun 27, 2002 · Adverse reactions to rifampin (RIF) and ethambutol (EMB) have been well documented (6–8), although causality of these drugs may be less certain ...METHODS · RESULTS · DISCUSSION
[127]
Tuberculosis Treatment and Case Outcomes - CDC
Nov 5, 2024 · 94.0% of persons with TB disease received at least part of their treatment for TB disease through DOT, and. 64.8% of persons with TB disease ...
[128]
A systematic review on adherence, cost of treatment observation ...
Oct 15, 2024 · Our study compares two methods of monitoring tuberculosis treatment: Video-observed therapy (VOT) and directly observed therapy (DOT).
[129]
1.3 Drug-resistant TB - World Health Organization (WHO)
Globally, the estimated proportion of new TB cases with MDR/RR-TB changed from 4.1% (95% UI: 3.1–5.0%) in 2015 to 3.2% (95% UI: 2.5–3.8%) in 2023; the estimated ...
[130]
Drug Resistance Mechanisms in Mycobacterium tuberculosis - NIH
The most prevalent mutation found is at position −15C/T and is more commonly associated with low level resistance to isoniazid (MIC < 1 µg/mL). Mutations in ...
[131]
Molecular Basis of Drug Resistance in Mycobacterium tuberculosis
Mutations in katG result in a reduced ability to form the INH-NAD adduct (33) and a high level of INH resistance. The most common mutation occurring in clinical ...
[132]
Multi‐drug resistance and compensatory mutations in ...
Mar 13, 2025 · Here, we found strong interactions between intrinsic factors including drug resistance-associated mutations, fitness-compensatory mutations, and ...INTRODUCTION · MATERIALS AND METHODS · RESULTS · DISCUSSION
[133]
2.4 Drug-resistant TB: treatment enrolment, coverage and outcomes
Globally in 2023, 175 923 people were enrolled on treatment for MDR/RR-TB. This was a small decrease from 177 912 in 2022 (-1.1%). Most of those enrolled on ...
[134]
Bedaquiline | Working Group for New TB Drugs
Bedaquiline is a member of the diarylquinoline class of drugs and has a unique mechanism of action, targeting the adenosine triphosphate (ATP) synthase enzyme ...
[135]
Mechanism of Action, Resistance, Synergism, and Clinical ... - NIH
Oct 7, 2021 · Delamanid (DLM) is a nitro-dihydro-imidazooxazole derivative utilized to treat MDR-TB. DLM has distinct mechanism of action, inhibiting methoxy- and keto- ...
[136]
Investigation of delamanid, bedaquiline, and linezolid resistance ...
Aug 15, 2025 · BDQ inhibits the proton pump of ATP synthesis in M. tuberculosis by binding to subunit C of the ATP synthase, ultimately causing bacterial death ...
[137]
Updated Guidelines on the Treatment of Drug-Susceptible ... - CDC
Jan 8, 2025 · The panel recommends two months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by two months of isonaizid and ...
[138]
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin ...
Jul 16, 2025 · Another 6-month treatment strategy emerged in 2024, comprising a regimen with bedaquiline, delamanid, linezolid, levofloxacin, and clofazimine; ...
[139]
Treatment outcomes of extensively drug-resistant tuberculosis in ...
Jul 15, 2025 · Among 3362 patients with pre-extensively drug-resistant tuberculosis, 2273 had a successful outcome, corresponding to a pooled estimate of 67·7% ...
[140]
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible ...
Jan 29, 2025 · Consistent results across all the analyses support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant ...
[141]
Bacillus Calmette-Guérin (BCG) Vaccine in America and Overseas
Nov 13, 2024 · Of the 180 countries with available data, 157 have universal BCG vaccination programs for infants to prevent severe forms of TB [14]. Some ...
[142]
Protection against tuberculosis by Bacillus Calmette-Guérin (BCG ...
Dec 31, 2021 · Efficacy rates of BCG for protection against TB disease have ranged from an absence of clinically relevant effects to substantial protection. A ...
[143]
BCG‐induced protection against Mycobacterium tuberculosis ...
Mar 12, 2021 · BCG-mediated protection against TB has historically been attributed to vaccine-induced memory CD4+ T cells which rapidly secrete Th1 cytokines ...
[144]
Key advances in vaccine development for tuberculosis—success ...
Oct 13, 2023 · The success of BCG at preventing childhood TB would suggest that its efficacy wanes with age, although this can vary greatly between studies.
[145]
Geographic latitude and the efficacy of bacillus Calmette-Guérin ...
Many factors that vary with latitude may influence the effectiveness of BCG vaccine by modifying the susceptibility of human hosts, the pathogenecity of the ...
[146]
The success and failure of BCG — implications for a novel ... - Nature
Jul 11, 2005 · The efficacy of BCG in adults is particularly poor in tropical and subtropical regions. Studies in animal models of TB, supported by data from ...
[147]
BCG vaccines - World Health Organization (WHO)
BCG vaccine is contraindicated in people with impaired immunity, and WHO does not recommend BCG vaccination for children with symptomatic HIV infection.
[148]
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent ...
The vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns.<|separator|>
[149]
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 ...
Mar 19, 2024 · In GSK's Phase 2b trial, M72/AS01E provided approximately 50% protection (13/1626 versus 26/1663) against progression to active pulmonary ...Missing: subunit 2023
[150]
Vaccination Against Tuberculosis: Revamping BCG by Molecular ...
Feb 26, 2020 · A central part of this treatise is the description of the viable BCG-based vaccine, VPM1002, currently undergoing phase III clinical trial ...
[151]
New TB Vaccine Research - World Health Organization (WHO)
Recently, an investigational TB vaccine candidate (M72/AS01E) was found to be significantly protective against TB disease in a Phase IIb trial conducted in ...
[152]
Tracking changes in national BCG vaccination policies and ...
Jan 17, 2022 · A large number of countries in the BCG Atlas (156/194 countries) maintain universal neonatal BCG vaccination, of which 51 are considered low TB ...
[153]
an overview of the WHO End TB Strategy 2025 milestones
By 2030, the strategy aims for a 75% reduction in the absolute number of TB deaths compared with the 2020 baseline, a 50% reduction in the TB incidence rate, ...
[154]
The End TB Strategy
### Summary of End TB Strategy Milestones and Case Detection Targets
[155]
Active case finding - Screening - World Health Organization (WHO)
Household contacts and other close contacts should be systematically screened for active TB. People living with HIV should be systematically screened for active ...
[156]
Community-based active case-finding interventions for tuberculosis
Sep 16, 2025 · Community-based active case-finding interventions might identify and treat more people with tuberculosis disease than standard case detection.Table 1 · Table 2 · Table 3
[157]
Tuberculosis Infection Control | TB Prevention in Health Care Settings
Dec 15, 2023 · ... isolation (AII) rooms; and cleaning the air by using high efficiency particulate air (HEPA) filtration, or ultraviolet germicidal irradiation.
[158]
Tuberculosis Infection Control in Health-Care Facilities
Oct 5, 2016 · UVGI is effective in killing or inactivating airborne M. tuberculosis. Typically, the optimal wavelength for UV germicidal radiation is 254 nm ...
[159]
Prevention and control of tuberculosis transmission in healthcare ...
Mar 13, 2025 · Ultraviolet germicidal irradiation (UVGI) is effective at inactivating airborne bacteria and in reducing the risk of M. tuberculosis ...
[160]
Directly observed treatment, short-course (DOTS): ensuring cure of ...
As of 1999, more than 110 countries are implementing the DOTS strategy. Quality of both diagnosis and treatment are markedly better than in previous programmes.
[161]
Digital adherence technologies for the management of tuberculosis ...
Oct 11, 2018 · In this article, we describe the landscape of DATs that are being used in research or clinical practice by TB programmes and highlight priorities for research.
[162]
WHO global genomic surveillance strategy for pathogens with ...
WHO's strategy is a 10-year framework to strengthen genomic surveillance, monitoring pathogens, and by 2032, all 194 member states have timely access to ...
[163]
Molecular Surveillance | Reported Tuberculosis in the United ... - CDC
Nov 5, 2024 · A total number of 1,110 tuberculosis (TB) disease clusters were reported nationally in 2021–2023 compared with 987 in 2020–2022.
[164]
The Social Determinants of Tuberculosis: From Evidence to Action
For example, poor ventilation and overcrowding in homes, workplaces, and communities increase the likelihood of uninfected individuals being exposed to TB ...
[165]
Community-based strategies for tuberculosis control in migrant ...
Oct 15, 2025 · Social and migration-related determinants significantly shape TB vulnerability among migrant communities. Integrating these determinants ...
[166]
A one health-focused literature review on bovine and zoonotic ...
The review analyzes the challenges and risk factors for bTB and zTB; and proposes One Health-based recommendations for control of M. bovis infection in humans ...Missing: migration | Show results with:migration
[167]
Koch's Discovery of the Tubercle Bacillus - CDC
On March 24, 1882, Robert Koch announced to the Berlin Physiological Society that he had discovered the cause of tuberculosis. Three weeks later, on April 10, ...
[168]
The history of tuberculosis: from the first historical records to ... - NIH
Robert Koch presented this extraordinary result to the Society of Physiology in Berlin on 24 March 1882, determining a milestone in the fight against TB [52].
[169]
Robert Koch – Facts - NobelPrize.org
Robert Koch, who had conducted a range of important studies on illnesses caused by microorganisms, discovered and described the TB bacterium in 1882.
[170]
History of BCG Vaccine - PMC - NIH
In 1921, Calmette decided that the time was ripe for a trial of the vaccine in man. The first human administration of BCG was by Benjamin Weill-Halle (1875-1958) ...
[171]
History of World TB Day - CDC
Dec 5, 2024 · On March 24, 1882, Dr. Robert Koch announced the discovery of Mycobacterium tuberculosis, the germ that causes tuberculosis (TB).
[172]
Tuberculosis: the sanatorium season in the early 20th century - PMC
Vaccination against tuberculosis with the bacillus Calmette-Guérin (BCG) was first seen as holding great promise, but was shelved after the “Lübeck disaster” ...
[173]
Bovine Tuberculosis and the Establishment of an Eradication ...
The significance of the identification of Mycobacterium bovis as a zoonotic pathogen in 1882 was not initially recognized. ... Robert Koch regarding bovine ...
[174]
A Brief History of Milk Hygiene and Its Impact on Infant Mortality from ...
Oct 1, 2018 · In 1907, the Germans reported that M. bovis did indeed infect humans. Likewise in 1911, the British Commission reported that although M.
[175]
Tuberculosis, Drug Resistance, and the History of Modern Medicine
Sep 6, 2012 · In November 1944, a patient with tuberculosis received streptomycin and was declared cured of the disease. Other cases of successful treatment ...
[176]
Treatment of Tuberculosis. A Historical Perspective - PubMed
In 1952, isoniazid opened the modern era of treatment; it was inexpensive, well tolerated, and safe. In the early 1960s, ethambutol was shown to be effective.
[177]
History of Tuberculosis - Global TB Center - Rutgers University
Following streptomycin, p-aminosalicylic acid (1949), isoniazid (1952), pyrazinamide (1954), cycloserine (1955), ethambutol (1962), and rifampin (rifampicin ...
[178]
WHO declares tuberculosis a global emergency
World Health Organization. WHO declares tuberculosis a global emergency. Soz Präventivmed 38, 251–252 (1993).
[179]
WHO ENDORSES NEW RAPID TUBERCULOSIS TEST
Dec 8, 2010 · The new, rapid and fully automated Xpert® MTB/RIF test is a real time cartridge-based automated DNA amplification test that will deliver a highly accurate ...Missing: 1993 | Show results with:1993
[180]
Shorter TB treatment regimen shown to be safe and effective in ...
Jun 19, 2024 · The safety and efficacy of the standard 9-month treatment regimen recommended by WHO for programmatic use in 2020 had already been established.Missing: 2020s | Show results with:2020s
[181]
endTB clinical trial results
Nov 15, 2023 · The endTB trial compared five experimental 9-month treatment regimens for treating MDR/RR-TB containing one or two new TB drugs, bedaquiline and ...